Quarkonium production in high energy proton-proton and proton-nucleus collisions

We present a brief overview of the most relevant current issues related to quarkonium production in high energy proton-proton and proton-nucleus collisions along with some perspectives. After reviewing recent experimental and theoretical results on quarkonium production in pp and pA collisions, we discuss the emerging field of polarisation studies. Thereafter, we report on issues related to heavy-quark production, both in pp and pA collisions, complemented by AA collisions. To put the work in a broader perspective, we emphasize the need for new observables to investigate quarkonium production mechanisms and reiterate the qualities that make quarkonia a unique tool for many investigations in particle and nuclear physics.Comment: Overview for the proceedings of QUARKONIUM 2010: Three Days Of Quarkonium Production in pp and pA Collisions, 29-31 July 2010, Palaiseau, France; 34 pages, 30 figures, Late

Consensus recommendations for the use of automated insulin delivery technologies in clinical practice

The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage

Safety, Pharmacokinetics, and Pharmacodynamics of the DR5 Antibody LBY135 Alone and in Combination with Capecitabine in Patients with Advanced Solid Tumors

Purpose: We evaluated the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, biologic activity, and antitumor efficacy of the DR5 antibody, LBY135 ± capecitabine. Experimental design: Escalating LBY135 was administered every 21 days, alone (Arm1) or with capecitabine (Arm2), to patients with advanced solid tumors. Results: In Arm1 (n=40), LBY135 (0.3–40 mg/kg) resulted in no dose-limiting toxicities; adverse events (AEs) included fatigue, hypotension, abdominal pain, dyspnea, and nausea. Stable disease (SD) was observed in 21/38 (55.3%) patients. In Arm2 (n=33), LBY135 (1–40 mg/kg) plus capecitabine resulted in 3 DLTs (each grade 3): dehydration and mucosal inflammation (1 mg/kg), colitis (20mg/kg), and diarrhea (40 mg/kg). AEs included fatigue, nausea, dyspnea, and vomiting. Partial response was observed in 2 patients (rectal and breast cancer) and SD in 12/27 (44.4%) patients. Mean elimination half-life of LBY135 ± capecitabine at saturation of clearance (≥10 mg/kg) ranged between 146–492 hours. Immunogenicity was detected in 16/73 (22%) patients, of which 6 patients experienced reduced LBY135 exposure with repeat dosing. M30/M65 levels were not predictive for LBY135 response. FDG-PET responses were not consistently associated with RECIST responses. Conclusions: LBY135 was well tolerated up to 40mg/kg, the maximal dose administered; no MTD for LBY135 ± capecitabine was defined. Clearance was saturated at doses ≥10 mg/kg